ALVO News

Alvotech Announces Proposed $125 Million Public Offering and Concurrent Private Placement of Ordinary Shares

Alvotech Announces Pricing of $152 Million Public Offering of Ordinary Shares and Concurrent Private Placement

Alvotech Announces Pricing of $152 Million Public Offering of Ordinary Shares and Concurrent Private Placement

Alvotech Announces Proposed $125 Million Public Offering and Concurrent Private Placement of Ordinary Shares

Alvotech Announces Proposed $125 Million Public Offering and Concurrent Private Placement of Ordinary Shares

Alvotech announces FDA acceptance of Biologics License Application for AVT16, a proposed interchangeable biosimilar to Entyvio®

Alvotech announces FDA acceptance of Biologics License Application for AVT16, a proposed interchangeable biosimilar to Entyvio®

Alvotech announces resubmission of U.S. Biologics License Applications for AVT05, a proposed biosimilar to Simponi® and Simponi Aria®, and AVT06, a proposed biosimilar to Eylea®

Alvotech announces resubmission of U.S. Biologics License Applications for AVT05, a proposed biosimilar to Simponi® and Simponi Aria®, and AVT06, a proposed biosimilar to Eylea®

Alvotech to present at upcoming investor conferences in June